Summary
Major progress has been made in the treatment of patients with advanced urothelial tract tumors, using a systematic phase II approach in selected patients. At this time, DDP and MTX, singly, seem to induce the largest number of responses, while VLB and ADM, singly, are good secondary agents. The combinations of DDP+ADM, and VLB+MTX appear to be somewhat more effective than the single drug components, and hopefully a four-drug combination may be even more effective. Since significant antitumor activity is achieved with the drugs now available, we plant to initiate a randomized phase-III study in patients with stage-D tumors after preoperative irradiation and radical cystectomy with lymph node dissection. The data at Memorial Sloan-Kettering Cancer Center indicate a 70% death rate at 1 year, and 87% at 2 years, despite radiation therapy and cystectomy; for such cases, therefore, chemotherapy may be useful in prolonging survival. While new drugs still need to be defined, transitional cell carcinoma of the urothelial tract must be considered a tumor responsive to chemotherapy; we may possibly be on the threshold of chemotherapeutically curative therapies.
Similar content being viewed by others
References
Blumenreich MS, Yagoda A, Natale RB, Watson RC (1982) Phase II trial of vinblastine sulfate for metastatic urothelial tract tumors. Cancer 50: 435–438
Natale RB, Yagoda A, Watson RC, Stover D (1980) Phase II trial of neocarcinostatin in patients with bladder and prostatic cancer: Toxicity of a 5-day IV bolus schedule. Cancer 45: 2836–2842
Natele RB, Yagoda A, Watson RC, Whitmore WF, Blumenreich MR, Braun DW (1981) Methotrexate: An active drug in bladder cancer. Cancer 47: 1246–1250
Natale RB, Yagoda A, Watson RC (1982) Phase II trial of AMSA (4′9-acridinylamino methanesulfon-m-anisidide) in prostatic cancer. Cancer Treat Rep 66: 208–209
Natale RB, Yagoda A, Kelsen DP, Gralla, Watson RC (1982) Phase II trial of PALA in hypernephroma and urinary bladder cancer. Cancer Treat Rep 66: 2091–2092
Needles B, Ahmed T, Blumenreich M, Yagoda A, Watson RC (1982) Phase II trial of vinblastine and methotrexate in urothelial tumors. Proc Am Assoc Cancer Res, p 422
Yagoda A (1977) Future implications of phase II chemotherapy trials in ninety-five patients with measurable advanced bladder cancer. Cancer Res 37: 2775–2780
Yagoda A (1980) Chemotherapy of metastatic bladder cancer. Cancer 45: 1879–1888
Yagoda A, Watson RC, Gonzales-Vitale JC, Grabstald H, Whitmore WF (1976) Cisdichlorodiammineplatinum (II) in advanced bladder cancer. Cancer Treat Rep 60: 917–923
Yagoda A, Watson RC, Whitmore WF, Grabstald H, Middleman MP, Krakoff IH (1977a) Adriamycin in advanced urinary tract cancer: Experience in 42 patients and a review of the literature. Cancer 39: 279–285
Yagoda A, Watson RC, Grabstald H, Barzell WE, Whitmore WF (1977b) Adriamycin and cyclophosphamide in advanced bladder cancer. Cancer Treat Rep 61: 97–99
Yagoda A, Watson RC, Kemeny N, Barzell WE, Grabstald H, Whitmore WF (1978) Diamminedichloride platinum II (DDP) and cyclophosphamide (CTX) in the treatment of advanced urothelial cancer. Cancer 41: 2121–2130
Yagoda A, Bosl G, Scher H (1982) Advances in chemotherapy. In: Javadpout N (ed) Recent advances in urologic cancer. Williams and Wilkins, Baltimore, pp 211–254
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Yagoda, A. Phase-II trials in patients with urothelial tract tumors. Cancer Chemother. Pharmacol. 11 (Suppl 1), S9–S12 (1983). https://doi.org/10.1007/BF00256709
Issue Date:
DOI: https://doi.org/10.1007/BF00256709